Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
QuintilesIMS
UBS
Moodys
Chubb
Covington
Julphar
Healthtrust

Generated: May 20, 2018

DrugPatentWatch Database Preview

ZELBORAF Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Zelboraf, and when can generic versions of Zelboraf launch?

Zelboraf is a drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and eighty-two patent family members in forty-four countries.

The generic ingredient in ZELBORAF is vemurafenib. One supplier is listed for this compound. Additional details are available on the vemurafenib profile page.
Summary for ZELBORAF
Drug patent expirations by year for ZELBORAF
Synonyms for ZELBORAF
[(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6 -dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]methanone
1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-
1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-
1029872-54-5
207SMY3FQT
3og7
4CA-1032
918504-65-1
A25476
AB0031775
AB01273970_03
AB01273970-01
AB1009703
ABP000429
AC-25010
ACN-030372
AK-56796
AKOS007930804
AM81259
AN-1313
ANW-69692
AOB87705
AX8212389
BC626573
BDBM50396483
BRAF(V600E) Kinase Inhibitor RO5185426
BRD-K56343971-001-02-3
C23H18ClF2N3O3S
CHEBI:63637
CHEMBL1229517
CS-0216
CTK8C3113
D09996
D0Y9EW
DB08881
DTXSID50238710
EX-A053
EX-A1335
FT-0660388
FT-0675792
FT-0689782
GPXBXXGIAQBQNI-UHFFFAOYSA-N
GTPL5893
HE070213
HE290987
HE413595
HMS3265M03
HMS3265M04
HMS3265N03
HMS3265N04
HMS3654P09
HSDB 8143
HY-12057
IN2235
J-522975
J-690009
KB-59765
KS-0000002Q
MCULE-7244406627
ME-0096
MFCD18074504
MolPort-009-200-481
N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide
n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide
N-(3-([5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE
N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine
N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-propane-1-sulfonamide
N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide
N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide
N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide
N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide
N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide
N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
NCGC00250399-01
NSC-761431
NSC761431
PB11741
PLX 4032
PLX-4032
PLX-4032(RG7204)/PLX4032
PLX4032
PLX4032 - Vemurafenib
PLX4032 ,Vemurafenib ,
PLX4032 (Vemurafenib)
PLX4032, RG7204, RO5185426, 1029872-54-5
PLX4032,Vemurafenib, RG7204, RO5185426, Zelboraf
propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
Q-3409
QCR-44
R-7204
RG 7204
RG-7204
RG7204
RL05788
Ro 51-85426
RO 5185426
RO-5185426
RO5185426
s1267
SC-54548
SCHEMBL298931
SR-01000941568
SR-01000941568-1
ST24048327
SYN1161
TC-158437
TRA0082406
UNII-207SMY3FQT
Vemurafenib
Vemurafenib (BRAF inhibitor)
Vemurafenib (JAN/USAN/INN)
Vemurafenib (PLX4032, RG7204)
Vemurafenib (PLX4032)
Vemurafenib [USAN:INN]
Vemurafenib, RG7204, RO5185426
Vemurafenib;PLX-4032
vemurafenibum
Y0473
Zelboraf (TN)
ZINC52509366
ZX-AFC000306

US Patents and Regulatory Information for ZELBORAF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for ZELBORAF

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,530,661 Process for the manufacture of pharmaceutically active compounds ➤ Sign Up
8,415,469 Compounds and methods for kinase modulation, and indications therefor ➤ Sign Up
8,329,724 Process for the manufacture of pharmaceutically active compounds ➤ Sign Up
8,067,434 Compounds and methods for development of Ret modulators ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for ZELBORAF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2, 5012-2012 Slovakia ➤ Sign Up PRODUCT NAME: VEMURAFENIB; REGISTRATION NO/DATE: EI/1/712/751/002 20120217
2012000043 Germany ➤ Sign Up PRODUCT NAME: VEMURAFENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
0120016 00059 Estonia ➤ Sign Up PRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012
90026-2 Sweden ➤ Sign Up PRODUCT NAME: VEMURAFENIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/12/751/001 20120217
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Medtronic
Moodys
McKesson
US Army
Cipla
Fish and Richardson
Teva
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.